ジャーナル: Cell Rep / 年: 2025 タイトル: Identification and engineering of potent bispecific antibodies that protect against herpes simplex virus recurrent disease. 著者: Chingwei V Lee / Hector Viadiu / Apurva Kalamkar / David I Bernstein / Andrew Pae / Xinchao Yu / Sylvia Wong / Fernando J Bravo / Sheng Ding / Elbert Seto / Magdeleine Hung / Yu Yu / Weimei ...著者: Chingwei V Lee / Hector Viadiu / Apurva Kalamkar / David I Bernstein / Andrew Pae / Xinchao Yu / Sylvia Wong / Fernando J Bravo / Sheng Ding / Elbert Seto / Magdeleine Hung / Yu Yu / Weimei Xing / Giuseppe A Papalia / Wei Kan / Brian Carr / Majlinda Thomas / Leah Tong / Priyanka Desai / Nadine Jarrousse / Alexandre Mercier / Meghan M Holdorf / Simon P Fletcher / Emma Abernathy / 要旨: Herpes simplex virus (HSV) causes lifelong infections, including oral and genital herpes. There is no vaccine, and current antivirals are only partially effective at reducing symptoms and ...Herpes simplex virus (HSV) causes lifelong infections, including oral and genital herpes. There is no vaccine, and current antivirals are only partially effective at reducing symptoms and transmission. Therapeutic antibodies offer a potentially long-acting treatment option, although efforts to pursue this have been limited. We performed an alpaca immunization campaign and discovered high-affinity antibodies that both neutralized and completely blocked cell-to-cell spread (CCS), a key mechanism by which HSV evades neutralizing antibodies. Unexpectedly, we found that engineering antibodies into a bispecific format targeting two viral glycoproteins dramatically increased antiviral potency. Solving the structures of three antibodies using cryo-electron microscopy (cryo-EM) revealed a mechanistic understanding of how the bispecific format could enhance potency. Lastly, these bispecific antibodies significantly reduced lesion development in the guinea pig model of genital herpes, demonstrating that delayed dosing after latency establishment can reduce disease and confirming their potential as a transformative treatment option.
全体 : D7 Neutralizing Nanobody bound to the HSV Glycoprotein D
全体
名称: D7 Neutralizing Nanobody bound to the HSV Glycoprotein D
要素
複合体: D7 Neutralizing Nanobody bound to the HSV Glycoprotein D
タンパク質・ペプチド: Anti-Nb Fab Heavy chain
タンパク質・ペプチド: Ig-like domain-containing protein
タンパク質・ペプチド: D7 Neutralizing Nanobody against HSV Glycoprotein D
タンパク質・ペプチド: Glycoprotein D
リガンド: water
-
超分子 #1: D7 Neutralizing Nanobody bound to the HSV Glycoprotein D
超分子
名称: D7 Neutralizing Nanobody bound to the HSV Glycoprotein D タイプ: complex / ID: 1 / 親要素: 0 / 含まれる分子: #1-#4 詳細: There are 4 molecules in the complex. A HSV Glycoprotein D monomer neutrilized by the D7 Nanobody and one tool Fab to enable CryoEM studies (light and heavy chains).
由来(天然)
生物種: Homo sapiens (ヒト)
-
分子 #1: Anti-Nb Fab Heavy chain
分子
名称: Anti-Nb Fab Heavy chain / タイプ: protein_or_peptide / ID: 1 / コピー数: 1 / 光学異性体: LEVO